Calprotectin May Be Biomarker of IPF Severity

Calprotectin May Be Biomarker of IPF Severity
4.5
(16)

Calprotectin may serve as a blood biomarker for disease severity in patients with idiopathic pulmonary fibrosis (IPF), a new study indicates.

Calprotectin blood levels are significantly higher in IPF patients and show a correlation with measures of lung function.

The study, “Serum calprotectin as new biomarker for disease severity in idiopathic pulmonary fibrosis: a cross-sectional study in two independent cohorts,” was published in the journal BMJ Open Respiratory Research.

Pulmonary function tests are the standard tools to assess disease progression in IPF. However, they have weaknesses, including variables among patients, poor sensitivity to change, and difficulties in acquisition. That is why alternative non-invasive biomarkers for the assessment of IPF severity and disease progression are urgently needed.

Calprotectin is a protein produced by immune cells called neutrophils, which are thought to contribute to IPF disease. This protein has been investigated as a biomarker and treatment target in various medical conditions, including disease activity in inflammatory bowel diseases.

A team led by researchers at the Bern University Hospital, in Switzerland, decided to investigate the association of calprotectin blood levels and disease severity in IPF patients with the goal of establishing a potential role of calprotectin as a biomarker for the disease.

The study included 26 healthy volunteers (mean age 47.6 years) and 26 Swiss IPF patients (mean age 69.6). To validate their findings, the team also analyzed an independent group of 66 Spanish patients with IPF (mean age 71.3) from the Bellvitge University Hospital in Barcelona.

Patients with IPF in the Swiss and Spanish groups had smoked longer compared to healthy controls, and presented poorer pulmonary function parameters.

Calprotectin blood levels were measured and compared between healthy volunteers and IPF patients. Several clinical parameters were assessed, including physiological predictors of PF to measure disease severity and survival.

These disease predictors included: forced vital capacity (FVC, a measure of the amount of air that is forcibly exhaled after taking the deepest breath possible); volume of air that can be blown out forcibly in one second (FEV1); diffusing capacity for carbon monoxide (DLCO, a measure of the lungs’ ability to transfer oxygen to the blood); and the composite physiologic index (CPI), to assess the combined effect of each individual predictor.

Calprotectin blood levels were found to be significantly higher in patients with IPF compared with healthy controls (2.47 vs. 0.97 micrograms/mL) and correlated with disease severity, as measured by DLCO and CPI, in both IPF groups. When adjusting the data for age and sex these results remained the same.

Also, in the Swiss group, patients with higher calprotectin blood levels (2.85 micrograms/mL or greater) had significantly worse survival — 6.1 times higher mortality risk. In the validation group, the highest calprotectin levels (3.78 micrograms/mL or greater) did not significantly discriminate long-term mortality (increased risk of 1.54 times).

Overall, “serum [blood] calprotectin levels are significantly higher in patients with IPF compared with healthy controls and show a relevant correlation of calprotectin with disease severity measured by DLCO and CPI,” the researchers wrote.

“These findings suggest a potential role of calprotectin as a blood biomarker for disease severity in IPF”, they concluded.

The team noted that more studies are needed to confirm the findings and to reach definite conclusions regarding the relationship between calprotectin and IPF progression.

Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Total Posts: 110

Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.

×
Diana holds a PhD in Biomedical Sciences, with specialization in genetics, from Universidade Nova de Lisboa, Portugal. Her work has been focused on enzyme function, human genetics and drug metabolism.
Latest Posts
  • Krebs von den Lungen-6 protein, KL-6
  • Ofev analysis
  • quality of life, IPF symptoms
  • Calprotectin

How useful was this post?

Click on a star to rate it!

Average rating 4.5 / 5. Vote count: 16

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?